RU2014150850A - Нагруженные полипептидом роса-наночастицы для перорального введения - Google Patents
Нагруженные полипептидом роса-наночастицы для перорального введения Download PDFInfo
- Publication number
- RU2014150850A RU2014150850A RU2014150850A RU2014150850A RU2014150850A RU 2014150850 A RU2014150850 A RU 2014150850A RU 2014150850 A RU2014150850 A RU 2014150850A RU 2014150850 A RU2014150850 A RU 2014150850A RU 2014150850 A RU2014150850 A RU 2014150850A
- Authority
- RU
- Russia
- Prior art keywords
- nanoparticle
- nanoparticles
- metabolic
- biologically active
- peptide
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 26
- 238000000034 method Methods 0.000 claims abstract 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 14
- 229920001184 polypeptide Polymers 0.000 claims abstract 12
- 230000002503 metabolic effect Effects 0.000 claims abstract 10
- 239000007864 aqueous solution Substances 0.000 claims abstract 7
- 239000000178 monomer Substances 0.000 claims abstract 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000000839 emulsion Substances 0.000 claims abstract 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003960 organic solvent Substances 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract 2
- 229920001091 Poly(octyl cyanoacrylate) Polymers 0.000 claims abstract 2
- 230000002378 acidificating effect Effects 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 239000008346 aqueous phase Substances 0.000 claims abstract 2
- 239000007900 aqueous suspension Substances 0.000 claims abstract 2
- 238000002296 dynamic light scattering Methods 0.000 claims abstract 2
- 238000001704 evaporation Methods 0.000 claims abstract 2
- 230000008020 evaporation Effects 0.000 claims abstract 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims abstract 2
- 239000000859 incretin Substances 0.000 claims abstract 2
- 230000002473 insulinotropic effect Effects 0.000 claims abstract 2
- 229940065472 octyl acrylate Drugs 0.000 claims abstract 2
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 claims abstract 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000012074 organic phase Substances 0.000 claims abstract 2
- 238000006116 polymerization reaction Methods 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020710 Hyperphagia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 235000020830 overeating Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004382 Amylase Substances 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920000855 Fucoidan Polymers 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647633P | 2012-05-16 | 2012-05-16 | |
| US61/647,633 | 2012-05-16 | ||
| PCT/IB2013/000964 WO2013171570A1 (en) | 2012-05-16 | 2013-05-16 | Polypeptide loaded poca nanoparticles for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014150850A true RU2014150850A (ru) | 2016-07-10 |
Family
ID=48577784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014150850A RU2014150850A (ru) | 2012-05-16 | 2013-05-16 | Нагруженные полипептидом роса-наночастицы для перорального введения |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150342897A1 (enExample) |
| EP (1) | EP2849775A1 (enExample) |
| JP (1) | JP2015523332A (enExample) |
| KR (1) | KR20150010953A (enExample) |
| CN (1) | CN104411321A (enExample) |
| AU (1) | AU2013261214A1 (enExample) |
| CA (1) | CA2873536A1 (enExample) |
| IN (1) | IN2014DN09297A (enExample) |
| RU (1) | RU2014150850A (enExample) |
| WO (1) | WO2013171570A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104799440B (zh) * | 2014-01-23 | 2016-06-08 | 香港纺织及成衣研发中心有限公司 | 改善代谢综合症的功能服及其制造方法 |
| CN105342999A (zh) * | 2014-08-18 | 2016-02-24 | 山东绿叶制药有限公司 | 艾塞那肽口服纳米粒 |
| CN109675020B (zh) * | 2019-01-11 | 2021-05-04 | 浙江大学 | 一种口服glp-1多肽类纳米制剂及其制备方法和应用 |
| WO2022132454A1 (en) | 2020-12-18 | 2022-06-23 | Spectrum Brands, Inc. | Grooming tool for animal and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
| DK1019077T4 (da) | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
| JP2003522721A (ja) | 1997-11-14 | 2003-07-29 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規なエキセンジンアゴニスト化合物 |
| JP2001523688A (ja) | 1997-11-14 | 2001-11-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規エキセンジン・アゴニスト化合物 |
| ATE366115T1 (de) | 1998-02-13 | 2007-07-15 | Amylin Pharmaceuticals Inc | Inotropische und diuretische effekte von exendin und glp-1 |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| MX2007016039A (es) | 2005-06-17 | 2008-10-27 | Univ North Carolina | Metodos, sistemas y materiales de fabricacion de nanoparticulas. |
| US20080138418A1 (en) * | 2006-12-07 | 2008-06-12 | Tong Shen Enterprise Co., Ltd. | Nanoparticles composed of alkyl-cyanoacrylate polymers |
| CN101896337B (zh) | 2007-10-12 | 2013-10-30 | 流体科技公司 | 用于生产颗粒和图案化膜的系统和方法 |
-
2013
- 2013-05-16 EP EP13727643.2A patent/EP2849775A1/en not_active Withdrawn
- 2013-05-16 RU RU2014150850A patent/RU2014150850A/ru not_active Application Discontinuation
- 2013-05-16 US US14/401,333 patent/US20150342897A1/en not_active Abandoned
- 2013-05-16 WO PCT/IB2013/000964 patent/WO2013171570A1/en not_active Ceased
- 2013-05-16 KR KR20147031771A patent/KR20150010953A/ko not_active Withdrawn
- 2013-05-16 AU AU2013261214A patent/AU2013261214A1/en not_active Abandoned
- 2013-05-16 JP JP2015512144A patent/JP2015523332A/ja active Pending
- 2013-05-16 CA CA2873536A patent/CA2873536A1/en not_active Abandoned
- 2013-05-16 CN CN201380031679.4A patent/CN104411321A/zh active Pending
- 2013-05-16 IN IN9297DEN2014 patent/IN2014DN09297A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2873536A1 (en) | 2013-11-21 |
| CN104411321A (zh) | 2015-03-11 |
| KR20150010953A (ko) | 2015-01-29 |
| IN2014DN09297A (enExample) | 2015-07-10 |
| AU2013261214A1 (en) | 2014-11-20 |
| EP2849775A1 (en) | 2015-03-25 |
| WO2013171570A1 (en) | 2013-11-21 |
| US20150342897A1 (en) | 2015-12-03 |
| JP2015523332A (ja) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Araujo et al. | In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy | |
| Pund et al. | Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa | |
| Brayden et al. | Oral delivery of peptides: opportunities and issues for translation | |
| Silva-Veiga et al. | Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin | |
| Frizzell et al. | Protein-loaded emulsion electrospun fibers optimized for bioactivity retention and pH-controlled release for peroral delivery of biologic therapeutics | |
| Salem et al. | Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal | |
| JP2010504993A5 (enExample) | ||
| Huh et al. | Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride | |
| TW201605446A (zh) | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之修飾釋放調配物 | |
| Sadhasivam et al. | Transdermal patches of chitosan nanoparticles for insulin delivery | |
| AU2022241136A1 (en) | Composite oromucosal film compositions comprising epinephrine particles | |
| CN101053550A (zh) | 天麻素鼻腔凝胶剂 | |
| Rawas-Qalaji et al. | Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study | |
| Xia et al. | Performance and toxicity of different absorption enhancers used in the preparation of Poloxamer thermosensitive in situ gels for ketamine nasal administration | |
| Yang et al. | Rhodojaponin III-loaded chitosan derivatives-modified solid lipid nanoparticles for multimodal antinociceptive effects in vivo | |
| Zhang et al. | Mucus as a barrier for biopharmaceuticals and drug delivery systems | |
| CN104706597A (zh) | 一种用于鼻腔给药的尼莫地平脂质体及其制备方法 | |
| CN104688678B (zh) | 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液 | |
| CN116407509A (zh) | 一种利格列汀长效缓释微球及其制备方法 | |
| US20150342897A1 (en) | Polypeptide loaded poca nanoparticles for oral administration | |
| Joshi et al. | A review on Sublingual drug delivery: enhancing bioavailability and therapeutic outcomes | |
| EP3373953A1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| US20180221451A1 (en) | Long acting liraglutide compositions | |
| CN105267202A (zh) | 升麻素在制药中的应用 | |
| Elhabal et al. | Innovative HPMC/PVP K90 Dissolving Microneedles Incorporating Tacrolimus-Loaded Cubosomes: A Novel Strategy for Managing Allergic Conjunctivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160719 |